Designing effective PLpro inhibitors is challenging due to the enzyme's highly conserved active site, which is similar to human deubiquitinating enzymes. This similarity raises the risk of off-target effects, leading to potential toxicity. Moreover, the dynamic nature of the enzyme's active site requires inhibitors to be highly specific and capable of forming stable interactions to achieve effective inhibition.
